Antibody Information
General Information of This Antibody
| Antibody ID | ANI0VBGKZ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Pivekimab |
|||||
| Organization | ImmunoGen, Inc. |
|||||
| Indication | Hematologic neoplasms |
|||||
| Synonyms |
G4732A; G4723A; G-4723A
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Chimeric IgG1-kappa |
|||||
| Antigen Name | Interleukin-3 receptor subunit alpha (IL3RA) |
Antigen Info | ||||
| ChEMBI ID | ||||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLVQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYNDGTKY
NEKFKGRATLTSDRSTSTAYMELSSLRSEDTAVYYCAREGGNDYYDTMDYWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLCLSPG Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
QVQLVQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYNDGTKY
NEKFKGRATLTSDRSTSTAYMELSSLRSEDTAVYYCAREGGNDYYDTMDYWGQGTLVTVS S Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLCLSPG Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GYIFTSSI
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
IKPYNDGT
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
AREGGNDYYDTMDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYRVNRLVDGVPS
RFSGSGSGNDYTLTISSLQPEDFATYYCLQYDAFPYTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
EIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYRVNRLVDGVPS
RFSGSGSGNDYTLTISSLQPEDFATYYCLQYDAFPYTFGQGTKVEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
QDINSY
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
RVN
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
LQYDAFPYT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Pivekimab sunirine [Apprpved in 2026]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
33%
|
|||
| Patients Enrolled |
Eligibility requires CD123+ hematologic malignancies (6 cohorts: relapsed/refractory BPDCN/AML/ALL/MDS/MPN or frontline BPDCN). Key exclusions: available standard therapies (Cohorts 1-5), active CNS disease (frontline), prior VOD, grade 4 capillary leak syndrome, or anticancer therapy within 14 days (28 days for checkpoint inhibitors).
|
||||
| Administration Dosage |
IMGN632 was administered by IV on 2 different schedules for participants with relapsed/refractory AML, ALL, or BPDCN.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03386513 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
|
||||
| Primary Endpoint |
Primary endpoint evaluates composite complete response rate (CR+CRc) in BPDCN patients per 21-day treatment cycles.
|
||||
| Other Endpoint |
Secondary endpoints include 24-month assessments of CR duration, treatment-emergent AEs (CTCAE v4.03), expanded response rates (CR+CRc+CRh), ORR (CR+CRc+CRh+CRi+PR), OS, transplant bridging rates, PK/immunogenicity of IMGN632, and transfusion independence conversion.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
59%
|
|||
| Patients Enrolled |
Eligibility requires adults (≥18) with CD123+ AML (excluding APL) confirmed by local flow/IHC, adequate organ function (LVEF≥45%, eGFR>30mL/min), and specific disease status per regimen: untreated (Regimen C expansion), relapsed/refractory (≤2 prior lines), or MRD+ post-CR (Regimen D). Key exclusions: active CNS disease, SOS/VOD history, IMGN632 hypersensitivity, uncontrolled infections, or recent anticancer therapy (14-day washout, 28-day for checkpoint inhibitors). Special provisions address transplant recipients (≥120-day interval, no ≥G2 GVHD) and unfit patients (age≥75 or comorbidities precluding intensive therapy).
Click to Show/Hide
|
||||
| Administration Dosage |
IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 on Days 1 to 7 of a 28 day cycle. Cycle 1 azacitidine dose in subsequent cohorts may be reduced.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04086264 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
|
||||
| Primary Endpoint |
Primary objectives include evaluating safety/tolerability and determining RP2D of IMGN632 combinations (with azacitidine/venetoclax) in relapsed/refractory CD123+ AML over ~3 years through TEAE monitoring, while assessing preliminary antileukemic activity (CR/CRh/CRp/CRi/MLFS/PR) and MRD levels via central flow cytometry over ~18-20 months.
|
||||
| Other Endpoint |
Secondary endpoints comprise TEAE incidence (12-month), pharmacokinetic profiles (IMGN632/ADA concentrations), and MRD dynamics during dose escalation/expansion phases, with all parameters monitored for approximately 7-12 months using standardized analytical methods.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligibility requires adults (≥18) with untreated CD123+ AML (excluding APL/FLT3-mutated cases) and ELN adverse-risk features, adequate organ function (LVEF≥45%, CrCl≥60mL/min), and TRM score ≤13.1. Exclusions include CML blast phase, uncontrolled infections, pregnancy, or prior grade ≥3 antibody hypersensitivity.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06034470 | Clinical Status | PHASE1 | ||
| Clinical Description |
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
|
||||
| Primary Endpoint |
Primary endpoint assesses dose-limiting toxicities (DLTs) during cycle 1 (42-day observation), defined as grade ≥4 organ toxicity or prolonged severe myelosuppression (ANC<500/uL & platelets<25,000/uL for >42 days post-FLAG-Ida initiation) per ELN criteria.
|
||||
| Other Endpoint |
Secondary outcomes include 5-year AE incidence (NCI CTCAE v5.0), MRD rates (flow cytometry), relapse-free/overall survival, complete remission rates, cytopenia duration, and transplant proportions, all analyzed via standard statistical methods (Wilcoxon, Fisher's exact, Kaplan-Meier).
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
Eligibility requires CD123+ hematologic malignancies (AML/ALL/MPAL) in patients aged 1-22 years (weight ≥10kg), stratified by cohort: relapsed/refractory disease (Cohort 1), first-relapse AML (Cohorts 2-3). Key requirements include adequate organ function (EF≥55%, CrCl≥70mL/min), CNS1-3 status without neurological symptoms, and specified washout periods from prior therapies (14 days for chemotherapy, 21 days for antibodies). Exclusions cover APL/JMML, Down syndrome, active infections, copper metabolism disorders, pregnancy/breastfeeding, and prior grade ≥3 VOD/SOS.
Click to Show/Hide
|
||||
| Administration Dosage |
Patients receive IMGN632 IV on days 1 and 22. Treatment repeats every 42 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05320380 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia
|
||||
| Primary Endpoint |
Primary objectives include determining RP2D for IMGN632 monotherapy (Cohort 1) and combination therapy with daunorubicin/cytarabine liposome (Cohort 2) using rolling 6 design during 42-day cycle 1 DLT evaluation, while assessing flow-based ORR (CR/CRi/CRp) in Cohort 1 and MRD-negative response rates (<0.01% blasts) after two treatment cycles in pediatric AML patients (Cohort 3) through Fisher's Exact test comparisons.
Click to Show/Hide
|
||||
| Other Endpoint |
Pharmacokinetic parameters (AUC, Cmax, Vss, t1/2, CL, Tmax) will be analyzed via non-compartmental methods during cycles 1-2 across all cohorts, with serial plasma sampling to characterize IMGN632 exposure profiles and establish dose-exposure relationships in pediatric/adolescent populations.
|
||||
References